Prognostic Factors in Patients With Advanced Pancreatic Adenocarcinoma Treated With Intra-Arterial Chemotherapy

Pancreas ◽  
2008 ◽  
Vol 36 (1) ◽  
pp. 56-60 ◽  
Author(s):  
Andrea Mambrini ◽  
Claudio Bassi ◽  
Paola Pacetti ◽  
Tito Torri ◽  
Calogero Iacono ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Pancreatic Adenocarcinoma ◽  
Advanced Pancreatic Adenocarcinoma

scholarly journals Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation

Cancer ◽  
2006 ◽  
Vol 107 (11) ◽  
pp. 2589-2596 ◽  
Author(s):  
Sunil Krishnan ◽  
Vishal Rana ◽  
Nora A. Janjan ◽  
James L. Abbruzzese ◽  
Morris S. Gould ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Pancreatic Adenocarcinoma ◽  
Locally Advanced ◽  
Locally Advanced Pancreatic Adenocarcinoma ◽  
Advanced Pancreatic Adenocarcinoma

scholarly journals Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?

2021 ◽  
Vol 11 (4) ◽  
pp. 245
Author(s):  
Laura Cortesi ◽  
Claudia Piombino ◽  
Angela Toss
Keyword(s):  
Prognostic Factors ◽  
Homologous Recombination ◽  
Pancreatic Adenocarcinoma ◽  
Objective Response ◽  
Metastatic Breast ◽  
Germline Mutations ◽  
Response To Treatment ◽  
Homologous Recombination Repair ◽  
Dna Breaks ◽  
Recombination Repair

The homologous recombination repair (HRR) pathway repairs double-strand DNA breaks, mostly by BRCA1 and BRCA2, although other proteins such as ATM, CHEK2, and PALB2 are also involved. BRCA1/2 germline mutations are targeted by PARP inhibitors. The aim of this commentary is to explore whether germline mutations in HRR-related genes other than BRCA1/2 have to be considered as prognostic factors or predictive to therapies by discussing the results of two articles published in December 2020. The TBCRC 048 trial published by Tung et al. showed an impressive objective response rate to olaparib in metastatic breast cancer patients with germline PALB2 mutation compared to germline ATM and CHEK2 mutation carriers. Additionally, Yadav et al. observed a significantly longer overall survival in pancreatic adenocarcinoma patients with germline HRR mutations compared to non-carriers. In our opinion, assuming that PALB2 is a high-penetrant gene with a key role in the HRR system, PALB2 mutations are predictive factors for response to treatment. Moreover, germline mutations in the ATM gene provide a better outcome in pancreatic adenocarcinoma, being more often associated to wild-type KRAS. In conclusion, sequencing of HRR-related genes other than BRCA1/2 should be routinely offered as part of a biological characterization of pancreatic and breast cancers.

scholarly journals A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma

Cancer ◽  
2017 ◽  
Vol 123 (23) ◽  
pp. 4556-4565 ◽  
Author(s):  
Maeve A. Lowery ◽  
Kenneth H. Yu ◽  
David Paul Kelsen ◽  
James J. Harding ◽  
John S. Bomalaski ◽  
...  
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Phase 1 ◽  
Advanced Pancreatic Adenocarcinoma
Sign in / Sign up

Export Citation Format

Share Document